Levy RH - Search Results

1

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM. Zhao P, et al. Among authors: levy rh. J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196. J Clin Pharmacol. 2009. PMID: 19246732

2

Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Garnett WR, Schmerler M, Rosenfeld W, Shah J, Pan WJ. Levy RH, et al. J Clin Pharmacol. 2004 Nov;44(11):1230-4. doi: 10.1177/0091270004268045. J Clin Pharmacol. 2004. PMID: 15496640 Clinical Trial.

3

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Ragueneau-Majlessi I, et al. Among authors: levy rh. Curr Drug Metab. 2007 Dec;8(8):810-4. doi: 10.2174/138920007782798135. Curr Drug Metab. 2007. PMID: 18220561

4

Past, Present, and Future of Drug-Drug Interactions.

Levy RH, Ragueneau-Majlessi I. Levy RH, et al. Clin Pharmacol Ther. 2019 Jun;105(6):1286-1288. doi: 10.1002/cpt.1349. Epub 2019 Feb 17. Clin Pharmacol Ther. 2019. PMID: 30773619 Review. No abstract available.

5

Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective.

McFeely SJ, Ritchie TK, Yu J, Nordmark A, Berglund EG, Levy RH, Ragueneau-Majlessi I. McFeely SJ, et al. Among authors: levy rh. J Clin Pharmacol. 2020 Aug;60(8):1087-1098. doi: 10.1002/jcph.1604. Epub 2020 Mar 20. J Clin Pharmacol. 2020. PMID: 32196692

6

Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Levy RH, et al. Ther Drug Monit. 2005 Apr;27(2):193-8. doi: 10.1097/01.ftd.0000153403.99478.1f. Ther Drug Monit. 2005. PMID: 15795651 Clinical Trial.

7

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Ragueneau-Majlessi I, et al. Among authors: levy rh. Clin Pharmacokinet. 2005;44(5):517-23. doi: 10.2165/00003088-200544050-00005. Clin Pharmacokinet. 2005. PMID: 15871637

8

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I. Yu J, et al. Among authors: levy rh. Drug Metab Dispos. 2019 Feb;47(2):135-144. doi: 10.1124/dmd.118.084905. Epub 2018 Nov 15. Drug Metab Dispos. 2019. PMID: 30442649 Review.

9

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Ragueneau-Majlessi I, et al. Among authors: levy rh. Epilepsy Res. 2001 Nov;47(1-2):55-63. doi: 10.1016/s0920-1211(01)00293-5. Epilepsy Res. 2001. PMID: 11673021 Clinical Trial.

10

Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly.

Levy R, Ragueneau-Majlessi I, Solanki B, Zannikos P, Yao C, Novak G. Levy R, et al. Epilepsy Res. 2008 Mar;79(1):22-30. doi: 10.1016/j.eplepsyres.2007.12.013. Epub 2008 Feb 14. Epilepsy Res. 2008. PMID: 18280116 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters